Where Opus Genetics Stands With Analysts
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Opus Genetics (NASDAQ:IRD) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Opus Genetics and provided 12-month price targets. The average target is $8.75, accompanied by a high estimate of $12.00 and a low estimate of $7.00. This current average has increased by 25.0% from the previous average price target of $7.00.
Exploring Analyst Ratings: An In-Depth Overview
The perception of Opus Genetics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Thomas Shrader | BTIG | Raises | Buy | $12.00 | $7.00 |
| Thomas Shrader | BTIG | Maintains | Buy | $7.00 | $7.00 |
| Thomas Shrader | BTIG | Announces | Buy | $7.00 | - |
| Mayank Mamtani | B. Riley Securities | Announces | Buy | $9.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Opus Genetics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Opus Genetics compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Opus Genetics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Opus Genetics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Opus Genetics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Opus Genetics Better
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Understanding the Numbers: Opus Genetics's Finances
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Decline in Revenue: Over the 3M period, Opus Genetics faced challenges, resulting in a decline of approximately -20.38% in revenue growth as of 30 September, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Opus Genetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -566.87%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -148.92%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Opus Genetics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -46.68%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Opus Genetics's debt-to-equity ratio is below the industry average at 0.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.